Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

BACKGROUND: In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory thera...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Respir Res
Egile Nagusiak: Cottin, Vincent, Richeldi, Luca, Rosas, Ivan, Otaola, Maria, Song, Jin Woo, Tomassetti, Sara, Wijsenbeek, Marlies, Schmitz, Manuela, Coeck, Carl, Stowasser, Susanne, Schlenker-Herceg, Rozsa, Kolb, Martin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2021
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7962343/
https://ncbi.nlm.nih.gov/pubmed/33726766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01668-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak